Trials / Completed
CompletedNCT01325688
PEP005 Gel - Evaluation of the Safety and Efficacy of Ingenol Mebutate Gel on a Superficial Basal Cell Carcinoma on the Trunk or Extremities
A Phase 2 Multi-centre, Parallel Group, Open Label Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, 0.05%, When Administered for up to Three Consecutive Days to a Superficial Basal Cell Carcinoma (sBCC) on the Trunk or Extremities
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 75 (actual)
- Sponsor
- Peplin · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is primarily designed to investigate whether treatment, once daily for up to three consecutive days, with PEP005 (ingenol mebutate) Gel, 0.05% will be safe and tolerable in patients with superficial Basal Cell Carcinoma (sBCC) lesions on the trunk and extremities.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PEP005 (ingenol mebutate) Gel, 0.05% | PEP005 (ingenol mebutate) Gel, 0.05% for up to three consecutive days |
| DEVICE | Aluminium disk | |
| DEVICE | OpSite(TM) disk |
Timeline
- Start date
- 2011-04-01
- Primary completion
- 2012-03-01
- Completion
- 2012-03-01
- First posted
- 2011-03-30
- Last updated
- 2016-02-26
Locations
7 sites across 1 country: Australia
Source: ClinicalTrials.gov record NCT01325688. Inclusion in this directory is not an endorsement.